Nicole Lemerond
Vermögen: - $ am 31.08.2026
Vermögen: - $ am 31.08.2026
Ms. Nicole Lemerond, CFA, is an Independent Director at MediciNova, Inc., an Independent Director at GeoVax Labs, Inc. and an Independent Director at InMed Pharmaceuticals, Inc. She is on the Board of Directors at MediciNova, Inc., GeoVax Labs, Inc. and InMed Pharmaceuticals, Inc. Ms. Lemerond was previously employed as a Managing Partner by NV Capital Management.
She received her undergraduate degree from Cornell University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MEDICINOVA, INC. -.--% | 23.06.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
GEOVAX LABS, INC. -.--% | 28.08.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
| 19.12.2025 | 0 ( -.--% ) | - $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| INMED PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 08.08.2022 |
| GEOVAX LABS, INC. | Direktor/Vorstandsmitglied | 31.08.2022 |
| MEDICINOVA, INC. | Direktor/Vorstandsmitglied | 04.08.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
NV Capital Management | Corporate Officer/Principal | 01.08.2022 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
InMed Pharmaceuticals, Inc.
InMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures prescription-based products for dermatology and ocular diseases | Health Technology |
MediciNova, Inc.
MediciNova, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company, which develops novel therapeutics for the treatment of neurological and other disorders | Health Technology |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GeoVax Labs, Inc.
GeoVax Labs, Inc. BiotechnologyHealth Technology Develops vaccines for diseases caused by Human Immunodeficiency Virus and other infectious agents | Health Technology |
NV Capital Management |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen